Skip to content
UCB
-
UCB expands autoimmune pipeline with US$2.2B Candid Therapeutics acquisition
The acquisition is expected to close by the end of the second quarter or early third quarter of 2026, pending regulatory approvals and customary closing conditions.
-
UCB acquires Neurona Therapeutics for USD1.15B to secure epilepsy cell therapy
The therapy, known as NRTX-1001, uses pluripotent stem cells engineered to regulate brain activity and repair damaged neural networks.
-
UCB to build USD2B AI-powered biologics plant in Georgia’s Rowen District
The 460,000-square-foot factory will sit on a 79-acre plot within the Rowen innovation district, near Dacula, Georgia, approximately 35 miles northeast of downtown Atlanta.